Table 2 Characteristic of new medicines applied for reimbursement decision between 2007 and 2016
2007–2013 First period (n = 85) | 2014–2016 Second period (n = 43) | |
|---|---|---|
Reimbursement | ||
yes | 75 | 42 |
no | 10 | 1 |
Duration a, b (right censored) | ||
approval_reimbursement decision | 29.24, (28.56) | 13.40, (9.66) |
approval_reimbursement trial | 10.85, (9.32) | 8.60, (6.77) |
reimbursement trial_ reimbursement decision | 18.39, (25.33) | 4.79, (5.73) |
Duration (reimbursed drugs only) | ||
approval_reimbursement decision | 20.61, (14.82) | 12.83, (9.04) |
approval_reimbursement trial | 9.95, (8.77) | 8.50, (6.82) |
reimbursement trial_ reimbursement decision | 10.66, (10.34) | 4.33, (4.92) |
Product types | ||
chemicals | 74 | 35 |
biologics | 11 | 8 |
Manufacturing types | ||
import | 68 | 36 |
local manufacturing | 11 | 2 |
local development and manufacturing | 6 | 5 |
ATC | ||
ATC J or L | 29 | 21 |
others | 56 | 22 |
Clinical effectiveness | ||
improved | 27 | 15 |
similar/non-inferior | 26 | 18 |
others | 32 | 10 |